CCT 241533; (3R,4S)-4-[[2-(5-氟-2-羟基苯基)-6,7-二甲氧基-4-喹唑啉基]氨基]-alpha,alpha-二甲基-3-吡咯烷甲醇 | 1262849-73-9

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: CCT 241533; (3R,4S)-4-[[2-(5-氟-2-羟基苯基)-6,7-二甲氧基-4-喹唑啉基]氨基]-alpha,alpha-二甲基-3-吡咯烷甲醇
• 中文别名: (3R,4S)-4-[[2-(5-氟-2-羟基苯基)-6,7-二甲氧基-4-喹唑啉基]氨基]-ALPHA,ALPHA-二甲基-3-吡咯烷甲醇；CCT241533;(3R,4S)-4-[[2-(5-氟-2-羟基苯基)-6,7-二甲氧基-4-喹唑啉基]氨基]-alpha,alpha-二甲基-3-吡咯烷甲醇
• 英文名称: CCT241533
• 英文别名: 4-fluoro-2-(4-((3S,4R)-4-(2-hydroxypropan-2-yl)pyrrolidin-3-ylamino)-6,7-dimethoxyquinazolin-2-yl)phenol；Cct-241533；4-fluoro-2-[4-[[(3S,4R)-4-(2-hydroxypropan-2-yl)pyrrolidin-3-yl]amino]-6,7-dimethoxyquinazolin-2-yl]phenol
• CAS: 1262849-73-9
• 化学式: C₂₃H₂₇FN₄O₄
• 分子量: 442.49
• InChiKey: HZASIAXCPXTISQ-NVXWUHKLSA-N

物化性质

• 沸点：
  569.4±50.0 °C(Predicted)
• 密度：
  1.327
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  109
• 氢给体数：
  4
• 氢受体数：
  9

制备方法与用途

生物活性

CCT241533 是一种有效且选择性的 CHK2 抑制剂，其 IC50 和 Ki 分别为 3 nM 和 1.16 nM。

靶点	活性
Chk2 (IC50)	3 nM
Chk1 (IC50)	245 nM
Chk2 (Ki)	1.16 nM

体外研究

CCT241533 氢氯化物抑制 CHK2，其 IC50 值为 3 nM，并且在 1 μM 浓度下对一组激酶的交叉反应性较低。X 射线晶体学证实 CCT241533 结合于 CHK2 的 ATP 袋中。CCT241533 阻断了 DNA 损伤后人类肿瘤细胞系中的 CHK2 活动，如通过抑制 S516 自磷酸化、带移动力学变化和 HDMX 降解来体现。CCT241533 并未增强多个细胞系中几种基因毒性剂的细胞毒作用。然而，它显著增强了两种结构不同的 PARP 抑制剂的细胞毒作用。单独使用一种 PARP 抑制剂可清晰地诱导 pS516 CHK2 信号，并且此激活被 CCT241533 消除。HT-29、HeLa 和 MCF-7 细胞中 CCT241533 的细胞生长抑制 IC50 (GI50) 分别为 1.7 μM、2.2 μM 和 5.1 μM，由 SRB 染色测定。CCT241533 氢氯化物是强效的 CHK2 抑制剂（IC50 = 3 nM），对 CHK1 的选择性为 63 倍 (IC50 = 190 nM)，且具有低 hERG 抑制作用 (IC50 = 22 μM)。

反应信息

• 作为产物：
  描述：

  2,4-二氯-6,7-二甲氧基喹唑啉 在 盐酸 、 四(三苯基膦)钯 、 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醚 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 144.0h， 生成 CCT 241533; (3R,4S)-4-[[2-(5-氟-2-羟基苯基)-6,7-二甲氧基-4-喹唑啉基]氨基]-alpha,alpha-二甲基-3-吡咯烷甲醇
  参考文献：
  名称：

  Structure-Based Design of Potent and Selective 2-(Quinazolin-2-yl)phenol Inhibitors of Checkpoint Kinase 2

  摘要：

  Structure-based design was applied to the optimization of a series of 2-(quinazolin-2-yl)phenols to generate potent and selective ATP-competitive inhibitors of the DNA damage response signaling enzyme checkpoint kinase 2 (CHK2). Structure-activity relationships for multiple substituent positions were optimized separately and in combination leading to the 2-(quinazolin-2-yl)phenol 46 (IC(50) 3 nM) with good selectivity for CHK2 against CHK1 and a wider panel of kinases and with promising in vitro ADMET properties. Off-target activity at hERG ion channels shown by the core scaffold was successfully reduced by the addition of peripheral polar substitution. In addition to showing mechanistic inhibition of CHK2 in HT29 human colon cancer cells, a concentration dependent radioprotective effect in mouse thymocytes was demonstrated for the potent inhibitor 46 (CCT241533).

  DOI：

  10.1021/jm101150b

文献信息

• [EN] THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS OXY-PHÉNYL-ARYLES THÉRAPEUTIQUES ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009053694A1

  公开（公告）日：2009-04-30

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK2 kinase function, and in the treatment of diseases and conditions that are mediated by CHK2, that are ameliorated by the inhibition of CHK2 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

  本发明总体涉及治疗化合物领域，更具体地涉及如本文所述的某些氧基苯基芳基化合物（以下简称OPA化合物），其中，抑制检查点激酶2（CHK2）激酶功能。本发明还涉及包含此类化合物的药物组合物，以及使用此类化合物和组合物，在体内外抑制CHK2激酶功能，以及治疗由CHK2介导的疾病和状况，包括通过抑制CHK2激酶功能而改善的疾病和状况，等等，包括诸如癌症等增殖性疾病，可选地与另一剂联合使用，例如，（a）DNA拓扑异构酶I或II抑制剂；（b）DNA损伤剂；（c）抗代谢物或TS抑制剂；（d）针对微管的药剂；（e）电离辐射。
• Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use
  申请人：Collins Ian

  公开号：US20110201592A1

  公开（公告）日：2011-08-18

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK2 kinase function, and in the treatment of diseases and conditions that are mediated by CHK2, that are ameliorated by the inhibition of CHK2 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

  本发明涉及治疗化合物领域，更具体地涉及某些氧苯基芳基化合物（以下简称OPA化合物），如本文所述，该化合物在其中抑制检查点激酶2（CHK2）激酶功能。本发明还涉及包含这种化合物的制药组合物，以及在体外和体内使用这种化合物和组合物来抑制CHK2激酶功能，并治疗由CHK2介导，通过抑制CHK2激酶功能改善的疾病和病况，包括增殖性疾病，如癌症等，可选择与另一种药物一起使用，例如（a）DNA拓扑异构酶I或II抑制剂；（b）DNA损伤剂；（c）抗代谢物或TS抑制剂；（d）微管靶向药物；和（e）电离辐射。
• [EN] PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF<br/>[FR] DÉRIVÉ DE PHOSPHAMIDE, SON PROCÉDÉ DE FABRICATION ET SES UTILISATIONS<br/>[ZH] 一种磷酰胺衍生物及制备方法和用途
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2017133517A1

  公开（公告）日：2017-08-10

  公开了一种磷酰胺衍生物及制备方法和用途。特别公开了一种通式(I)所示化合物及其药学上可接受的盐或立体异构体 (I)，其中，G、L、Q、s如说明书中所定义。
• THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE
  申请人：Cancer Research Technology Limited

  公开号：EP2227460B1

  公开（公告）日：2012-06-20
• CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES
  申请人：THE CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US20190314374A1

  公开（公告）日：2019-10-17

  The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.